Nektar Therapeutics (NKTR) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $66.3 million.
- Nektar Therapeutics' Total Current Liabilities fell 183.92% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.3 million, marking a year-over-year decrease of 183.92%. This contributed to the annual value of $61.4 million for FY2024, which is 1976.05% up from last year.
- Nektar Therapeutics' Total Current Liabilities amounted to $66.3 million in Q3 2025, which was down 183.92% from $71.4 million recorded in Q2 2025.
- Nektar Therapeutics' 5-year Total Current Liabilities high stood at $140.0 million for Q3 2021, and its period low was $50.7 million during Q2 2023.
- In the last 5 years, Nektar Therapeutics' Total Current Liabilities had a median value of $68.2 million in 2022 and averaged $79.1 million.
- In the last 5 years, Nektar Therapeutics' Total Current Liabilities tumbled by 6724.7% in 2021 and then skyrocketed by 3534.71% in 2025.
- Quarter analysis of 5 years shows Nektar Therapeutics' Total Current Liabilities stood at $85.2 million in 2021, then dropped by 19.95% to $68.2 million in 2022, then decreased by 24.83% to $51.3 million in 2023, then rose by 19.76% to $61.4 million in 2024, then increased by 8.05% to $66.3 million in 2025.
- Its Total Current Liabilities was $66.3 million in Q3 2025, compared to $71.4 million in Q2 2025 and $70.9 million in Q1 2025.